Opthea Future Growth

Future criteria checks 5/6

Opthea is forecast to grow earnings and revenue by 59.9% and 62.9% per annum respectively while EPS is expected to grow by 59.7% per annum.

Key information

59.9%

Earnings growth rate

59.7%

EPS growth rate

Biotechs earnings growth	24.4%
Revenue growth rate	62.9%
Future return on equity	n/a
Analyst coverage	Good
Last updated	07 May 2024

Recent future growth updates

No updates

Recent updates

Opthea GAAP EPS of -$0.26 misses by $0.03

Aug 30

Opthea receives $170M in non-dilutive financing for OPT-302 in wet AMD

Aug 15

Earnings and Revenue Growth Forecasts

NasdaqGS:OPT - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2026	105	-31	72	72	7
6/30/2025	12	-145	-136	-128	7
6/30/2024	1	-180	-166	-161	7
12/31/2023	0	-162	-121	-121	N/A
9/30/2023	0	-152	-121	-121	N/A
6/30/2023	0	-143	-121	-121	N/A
3/31/2023	0	-137	-116	-116	N/A
12/31/2022	0	-132	-112	-112	N/A
9/30/2022	0	-113	-92	-92	N/A
6/30/2022	0	-93	-71	-71	N/A
3/31/2022	0	-75	-64	-64	N/A
12/31/2021	0	-57	-56	-56	N/A
9/30/2021	0	-51	-51	-51	N/A
6/30/2021	0	-45	-46	-46	N/A
3/31/2021	0	-39	-36	-36	N/A
12/31/2020	0	-31	-27	-27	N/A
9/30/2020	0	-21	-16	-16	N/A
6/30/2020	0	-11	-6	-6	N/A
3/31/2020	0	-10	-7	-7	N/A
12/31/2019	0	-12	-10	-10	N/A
9/30/2019	0	-13	-13	-13	N/A
6/30/2019	0	-15	-17	-17	N/A
3/31/2019	0	-13	-14	-14	N/A
12/31/2018	0	-12	-11	-11	N/A
9/30/2018	0	-12	-13	-13	N/A
6/30/2018	0	-13	-15	-15	N/A
3/31/2018	0	-12	-13	-13	N/A
12/31/2017	0	-12	-12	-11	N/A
9/30/2017	0	-8	N/A	-8	N/A
6/30/2017	0	-5	N/A	-5	N/A
3/31/2017	0	-5	N/A	-4	N/A
12/31/2016	0	-5	N/A	-3	N/A
9/30/2016	0	-5	N/A	-3	N/A
6/30/2016	0	-5	N/A	-3	N/A
3/31/2016	0	-4	N/A	-2	N/A
12/31/2015	0	-3	N/A	-1	N/A
9/30/2015	0	-3	N/A	-2	N/A
6/30/2015	0	-4	N/A	-4	N/A
3/31/2015	1	-4	N/A	-4	N/A
12/31/2014	1	-4	N/A	-4	N/A
9/30/2014	1	-4	N/A	-4	N/A
6/30/2014	1	-4	N/A	-4	N/A
3/31/2014	1	-3	N/A	-4	N/A
12/31/2013	1	-2	N/A	-4	N/A
9/30/2013	1	-3	N/A	-5	N/A
6/30/2013	1	-4	N/A	-5	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: OPT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.4%).

Earnings vs Market: OPT is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: OPT is expected to become profitable in the next 3 years.

Revenue vs Market: OPT's revenue (62.9% per year) is forecast to grow faster than the US market (8.3% per year).

High Growth Revenue: OPT's revenue (62.9% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if OPT's Return on Equity is forecast to be high in 3 years time

Opthea Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

Recent updates

Opthea Limited Announces Board Changes

Opthea Appoints Arshad M. Khanani as Chief Medical Advisor

Opthea Limited Completes Enrollment in First Pivotal Trial with Sozinibercept

Opthea Strengthens Team with Key Clinical and Regulatory Hires

Opthea Limited Announces Executive Changes

Opthea Limited Announces “Sozinibercept” as the Nonproprietary Drug Name for OPT-302

Opthea Limited Announces Executive Changes

Opthea Limited Appoints Anshul Thakral as Non-Executive Director of the Board

Opthea Limited Announces Phase 2B Trial Results of OPT-302 in Combination with Lucentis for Wet Amd Published in the Journal Ophthalmology

Opthea Limited Appoints Timothy E. Morris as Chief Financial Officer

Opthea Limited, Annual General Meeting, Nov 16, 2022

Opthea GAAP EPS of -$0.26 misses by $0.03

Opthea Secures up to USD 170 Million in Non-Dilutive Financing for OPT-302 in wet AMD

Opthea Limited, Annual General Meeting, Sep 26, 2022

Opthea Secures up to USD 170 Million in Non-Dilutive Financing for OPT-302 in wet AMD

Opthea receives $170M in non-dilutive financing for OPT-302 in wet AMD

Opthea Limited Announces Data for OPT-302 in Combination with Ranibizumab for Polypoidal Choroidal Vasculopathy Presented at ARVO 2022

Opthea Limited Announces Board Appointments

Opthea Limited Appoints Joel Naor, as Chief Medical Officer

Opthea Limited Announces Data for OPT-302 in Patients with PVC

Opthea Limited Expands Global Phase 3 ShORe and COAST Wet AMD Trials of OPT-302 into Canada

Opthea's OPT-302 Granted FDA Fast Track Designation for Wet Age-Related Macular Degeneration

Opthea Limited Treats First Patient in Phase 3 Trials of OPT-302

Opthea Limited Finalizes Study Designs and Start-Up Activities for Phase 3 Pivotal Clinical Trials of OPT-302 in Wet AMD

Opthea Limited' ADR Deleted from Other OTC

Opthea Limited Appoints Dr. Jeremy Levin as Director

Geoffrey Kempler Retires as A Director of Opthea Limited

Opthea Limited Announces Board Changes

An unknown buyer acquired a 49% stake in Antisense Therapeutics Limited (ASX:ANP) from Opthea Limited (ASX:OPT) for AUD 0.34 million.

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies